Original Research
Published on 27 Feb 2023
Primary refractory plasmablastic lymphoma: A precision oncology approach
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1129405
- 2,767 views
- 4 citations
Type at least 3 characters
1,748 articles
Articles
Original Research
Published on 27 Feb 2023
TRIM37 interacts with PTEN to promote the growth of human T-cell acute lymphocytic leukemia cells through regulating PI3K/AKT pathway
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1016725
- 2,420 views
- 1 citation
Original Research
Published on 27 Feb 2023
Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study “Cervax”
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1133348
- 2,150 views
- 2 citations
Original Research
Published on 27 Feb 2023
Hereditary predisposition to malignant myeloid hemopathies: Caution in use of saliva and guideline based on our experience
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1120829
- 1,545 views
- 2 citations
Editorial
Published on 24 Feb 2023
Editorial: Advances in the understanding of pathogenesis, diagnosis, and therapy of light chain amyloidosis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1163490
- 1,011 views
- 1 citation
Original Research
Published on 23 Feb 2023
Integrating copy number data of 64 iAMP21 BCP-ALL patients narrows the common region of amplification to 1.57 Mb
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1128560
- 1,915 views
- 4 citations
Original Research
Published on 23 Feb 2023
Developing mRNA signatures as a novel prognostic biomarker predicting high risk multiple myeloma
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1105196
- 2,704 views
- 1 citation
Perspective
Published on 23 Feb 2023
Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1063144
- 6,217 views
- 6 citations
Review
Published on 22 Feb 2023
The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1130617
- 4,092 views
- 6 citations
Review
Published on 22 Feb 2023
Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1047554
- 2,109 views
Original Research
Published on 21 Feb 2023
Prognostic value of lipid profile in adult hemophagocytic lymphohistiocytosis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1083088
- 2,131 views
- 5 citations
Editorial
Published on 21 Feb 2023
Editorial: The role of the bone marrow microenvironment in multiple myeloma evolution and therapy
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1157555
- 1,840 views
- 2 citations
Editorial
Published on 20 Feb 2023
Editorial: Biology and treatment of high-risk CLL
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2022.1109950
- 1,932 views
Original Research
Published on 17 Feb 2023
Multicolor flow cytometric assessment of Ki67 expression and its diagnostic value in mature B-cell neoplasms
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1108837
- 4,800 views
- 4 citations
Case Report
Published on 17 Feb 2023
Case report: Genomic analysis of a therapy-related chronic myelomonocytic leukemia with KMT2A rearrangement that progressed to acute myeloid leukemia with acute promyelocytic leukemia-like features
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1116418
- 2,581 views
Systematic Review
Published on 16 Feb 2023
Post-transplant cyclophosphamide versus anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation from unrelated donors: A systematic review and meta-analysis
in Hematologic Malignancies
Frontiers in Oncology
doi 10.3389/fonc.2023.1071268
- 3,293 views
- 7 citations